TORONTO, Aug. 18 /CNW/ - ARIUS Research Inc. ("ARIUS") (TSX: ARI) today
announced that Dr. David Young, President and CSO of ARIUS, will give a talk
on ARIUS' "FunctionFIRST(TM) Antibody Technology" at the International
Congress on Monoclonal Antibodies in Cancer in Washington, DC on August 19,
2006 at 4:40 p.m. local time.
Dr. Young has pioneered an approach to the discovery of antibody drugs to
treat cancer through ARIUS' unique FunctionFIRST(TM) platform. ARIUS uses
tumor tissues from patients to generate antibodies then uses functional
screening to select the ones that attack and kill cancer cells or prevent them
from growing. Dr. Young's presentation will review the various scientific
methods for antibody discovery and provide a description and discussion of the
benefits of the FunctionFIRST(TM) approach. His talk will also include a
review of the novel antibodies and targets produced by the ARIUS platform.
ARIUS has entered into collaborations with other biopharma companies such
as PDL Biopharma Inc., Takeda Pharmaceutical Company Limited and Oxford
BioMedica PLC based on the FunctionFIRST(TM) platform. ARIUS has also
out-licensed one of its lead programs to Genentech, Inc and is pursuing
additional partnerships to move the next cohort of antibody treatments into
human clinical trials.
About ARIUS
ARIUS is a biotechnology company dedicated to personalizing cancer
therapy through the discovery and development of novel anticancer monoclonal
antibodies (MAbs). Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies powerful MAbs
targeting a variety of cancer indications. This antibody generation engine has
enabled ARIUS to assemble a growing pipeline, which is used for commercial
collaborations and in-house development. ARIUS has ongoing partnerships with
key biotechnology and drug development companies. ARIUS is listed on the TSX
under the symbol "ARI".
Forward-Looking Statement
Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.
%SEDAR: 00013708E
